Henry Schein, Inc. (HSIC) Stock Price & How to Invest
Last updated November 2026
Short answer
Henry Schein (HSIC) is the largest distributor of dental and medical supplies to office-based practices, and the investment case rests on whether its higher-margin specialty products and practice-management software can carry earnings while the low-margin distribution business grows slowly. Buying it means owning a self-help and margin-repair story, currently supervised by KKR from two board seats, rather than a growth compounder. At $86.84 on October 16, 2026 the shares are up ~13% year to date and ~40% over the past year, valued at ~$9.9B, or about 16 times the ~$5.39 of adjusted EPS analysts expect for 2026.
HSIC stock price
As of 2026-11-16, Henry Schein, Inc. (HSIC) last closed at $84.96, up 19.2% over the past year. Over the past 52 weeks it has traded between $68.99 and $90.86.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Henry Schein, Inc.'s investor relations page. Walnut is informational, not investment advice.
HSIC key stats
At $84.96 on November 16, 2026, Henry Schein, Inc. (HSIC) has a market cap of $9.4B and a P/E of 23.3 on trailing earnings (14.1 on forward earnings).
- Market cap
- $9.4B
- P/E (trailing)
- 23.3
- P/E (forward)
- 14.1
- EPS (trailing 12 months)
- $3.65
- Price to book
- 3.0
- Beta
- 0.86
Market cap, P/E and yield are measured at the $84.96 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Henry Schein, Inc. (HSIC)?
The last two weeks for Henry Schein, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- HSIC closed at $84.96 on November 16, 2026, down 3.9% over the past five trading days (from $88.41).
- On November 16, 2026, Henry Schein, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
- On November 3, 2026, Henry Schein, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 3, 2026, Henry Schein, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 4, 2026, UBS raised its target to $95.00 from $94.00 (Neutral).
- On November 4, 2026, Evercore ISI Group lowered its target to $100.00 from $105.00 (Outperform).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Henry Schein, Inc. (HSIC) do?
Henry Schein sells the products a dental office or a physician's practice consumes every day: consumables, small equipment, implants, orthodontic aligners, endodontic and biomaterial products, plus the software that runs the front desk and the billing. It reports in three pieces. Global Distribution and Value-Added Services is the large, low-margin core that moves other manufacturers' goods to roughly a million customers across dozens of countries. Global Specialty Products covers the higher-margin implant, orthodontic and biomaterials lines the company mostly bought. Global Technology sells practice-management and revenue-cycle software, including the Dentrix family, and carries by far the best economics in the company (segment operating margin of roughly 27% in Q2 2026 on segment operating income of about $49 million). Specialty and technology together contribute around half of operating income on a small fraction of revenue, which is the whole strategic point.
The last three years have been unkind. A 2023 cyberattack knocked out ordering systems, dental patient traffic and equipment purchases stayed soft, and gross margins compressed through 2025. That drew in outside capital: KKR built a roughly 12% position in January 2025 and took two board seats, the standstill ceiling was later raised from 14.9% to 19.9%, and activist Ananym Capital pressed publicly for CEO succession, cost cuts and a review of the medical distribution business. Fred Lowery now runs the company against a restructuring and value-creation program targeting more than $200 million of margin improvement, with charges expected to run through 2027. Q2 2026 was the clearest sign it is working: sales of about $3.5 billion (up roughly 6.7%), internal local-currency growth of about 4.6%, non-GAAP EPS up about 15.5% to roughly $1.27, and raised full-year guidance. At roughly $9.9 billion of market value (a $86.84 share price on October 16, 2026) on about $13.6 billion of trailing revenue, the market is still paying a distributor's price for it, even after a ~13% gain in 2026 and ~40% over twelve months.
The management bench is also changing. On October 8, 2026 the company named Emmanuel Caprais, CFO of ITT from 2020 to May 2026, as its next chief financial officer, effective November 4; Ronald South, CFO for the past four years, moves to a senior advisory role. The company also said it plans to add a Chief Strategy and Transformation Officer and a technology leader. Third-quarter results land on November 3, with consensus at ~$1.36 of adjusted EPS on ~$3.48 billion of sales.
What's driving Henry Schein, Inc. (HSIC)?
1. Mix shift toward specialty and technology.
Distribution is a pennies-on-the-dollar business, while the technology segment earns roughly 27% operating margins and specialty products earns well above the corporate average. Management has been steering capital and acquisitions toward those two, and they now supply about half of operating income. Every point of mix shift moves consolidated margin more than any volume gain in core distribution can.
2. The value-creation and restructuring program.
The program launched in 2025 with KKR's involvement targets more than $200 million of margin improvement through pricing discipline, indirect procurement, private-label penetration and product mix. Q2 2026 gross margin reversed the compression seen through 2025, and non-GAAP operating margin improved roughly 25 basis points year over year. Restructuring charges are expected to continue into 2027, so reported results will keep lagging the adjusted numbers for a while. The incoming CFO, Emmanuel Caprais, and a planned Chief Strategy and Transformation Officer suggest management intends to run the program with new hires rather than only existing staff.
3. A recovering demand backdrop in dental and medical.
Internal local-currency growth accelerated from Q1 to Q2 2026, and the company raised full-year sales growth guidance to roughly 4.5% to 5.5%. Dental consumables track patient visits and medical distribution tracks office-based procedure volume, neither of which grows quickly, but both had been running below trend since 2023. A return to normal utilization is a meaningful swing factor for a business with this much operating leverage on fixed distribution costs. Consensus for 2026 sits at ~$13.9 billion of revenue and ~$5.39 of adjusted EPS, rising to ~$14.4 billion and ~$5.99 in 2027.
4. Governance pressure and portfolio decisions.
KKR sits on the board with a raised ownership ceiling, and Ananym has publicly argued for divesting medical distribution. Whether or not a divestiture happens, the presence of an engaged large holder raises the probability of buybacks, cost action and portfolio simplification being pursued faster than a founder-led board would have chosen. It also introduces the possibility of a structural transaction that the current valuation does not reflect.
What are the risks to Henry Schein, Inc. (HSIC)?
Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. Dental consumables and equipment demand depends on discretionary patient visits, and the softness that started in 2023 has not fully cleared. Tariffs and freight on imported dental and medical goods are a live cost input that cannot always be passed through quickly. The company has grown specialty and technology largely by acquisition, which carries integration risk and a large goodwill balance relative to equity. Manufacturers selling directly to practices, and pure-play e-commerce suppliers, continue to chip at the intermediary's role, and the 2023 cyberattack is a reminder of how concentrated the operational risk in an ordering platform can be. Leverage is not trivial either: Yahoo data show ~$3.8 billion of debt against ~$157 million of cash, and GAAP net margin of roughly 3% leaves little cushion. A CFO handover on November 4, 2026, the day after Q3 results, adds execution risk during the margin program.
What is the Henry Schein, Inc. (HSIC) forecast?
15 analysts publish price targets on HSIC, averaging $96.60 as of November 2026, or +13.7% against the $84.96 share price on November 16, 2026. The published targets run from $64.00 to $110.00, a moderate spread, and the ratings split 8 buy, 7 hold, 1 sell. Over the last six months there have been 7 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full HSIC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is HSIC a buy or a sell?
We give no verdict on Henry Schein, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Mix shift toward specialty and technology. Distribution is a pennies-on-the-dollar business, while the technology segment earns roughly 27% operating margins and specialty products earns well above the corporate average. The most optimistic published target, $110.00, assumes this works close to its best case.
The case against. Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. The most pessimistic target, $64.00, is roughly what HSIC is worth if this bites instead.
Read the full bull and bear case on HSIC, including what would have to change to break either one. Walnut is not an investment adviser.
Has Henry Schein, Inc. (HSIC) split its stock?
Yes. Henry Schein, Inc. (HSIC) has had 2 share splits in the last 10 years:
- 2:1 on September 15, 2017, so every share held became 2 shares.
- 1275:1000 on February 8, 2019, so every share held became 1.275 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of HSIC the day before the 1275:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Henry Schein, Inc. (HSIC) valued?
Market cap, P/E and dividend yield at today's price are in the HSIC key stats above. The business figures below come from Henry Schein, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$13.6B, up ~6.7% year over year in Q2 2026
- Margins (TTM): ~31% gross, ~5.8% operating, ~3% net
- Net income (TTM): ~$403M; GAAP EPS ~$3.43
- FY2026 guidance, non-GAAP diluted EPS: ~$5.29 to ~$5.39
- Price to trailing sales: ~0.73x
- Next earnings: Nov 3, 2026; consensus EPS ~$1.36 on ~$3.48B
As of October 2026: At $86.84 against guided non-GAAP EPS of about $5.29 to $5.39, HSIC trades near 16 times this year's adjusted earnings and about 14.5 times next year's consensus, but roughly 25 times trailing GAAP earnings, because restructuring charges running through 2027 keep reported profit well below the adjusted figure. The sales multiple, under 0.75 times, matters least for a distributor. The gap between the GAAP and adjusted multiples is effectively the market's discount on whether the margin program sticks.
Who competes with Henry Schein, Inc. (HSIC)?
Dental and medical distribution
Patterson Companies was the closest listed comparison until it was taken private in 2025, leaving Benco Dental as the other large dental competitor and Cardinal Health, McKesson, Owens and Minor and privately held Medline as the medical-supply overlap. These are scale and logistics businesses where the fight is over supplier terms, private label penetration and last-mile service, not product differentiation.
Specialty dental manufacturers
Straumann, Envista, Dentsply Sirona and Align Technology make the implants, orthodontic and restorative products that Henry Schein both distributes and, through its own specialty brands, competes against. This is the awkward part of the model: growing the specialty portfolio pits Henry Schein against suppliers it also depends on for distribution volume.
Practice-management software
Dentrix competes with cloud-first challengers such as Curve Dental, CareStack and Planet DDS, along with software owned by equipment manufacturers. It is the highest-margin part of Henry Schein, and its installed Dentrix product faces dental practices moving to cloud software, which the cloud-based Dentrix Ascend line is meant to address.
What stocks are similar to Henry Schein, Inc. (HSIC)?
Other names that sit close to HSIC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Henry Schein, Inc. (HSIC)
There are three common ways to get HSIC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HSIC sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where HSIC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Henry Schein, Inc. (HSIC)
HSIC trades like a distributor and is trying to earn the multiple of a specialty and software business, and the 2026 numbers are the first real evidence that the shift is showing up in profit. Q3 results on November 3, 2026, the first day under a new CFO, are the next check on whether that continues.
More on Henry Schein, Inc. (HSIC)
Whether HSIC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HSIC a buy or a sell?, and where the stock could go from here in the HSIC stock forecast.
For income investors, whether HSIC pays a dividend and how the payout looks is covered in does HSIC pay a dividend? And to weigh HSIC against a peer, read the full side-by-side comparisons: HSIC vs MCK and HSIC vs MDLN.
Wondering how HSIC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Henry Schein, Inc.
Ask Walnut's AI anything about HSIC and see how it fits what you own.
FAQ
What does Henry Schein actually do?
+
It is a distributor. Henry Schein buys dental and medical products from thousands of manufacturers and resells them to office-based dentists and physicians, roughly a million customers worldwide, alongside its own specialty product brands (implants, orthodontics, biomaterials) and practice-management software such as Dentrix.
How do you invest in HSIC?
+
HSIC trades on the NasdaqGS, so any US brokerage that offers listed equities can hold it. It also sits inside broad health care and mid-cap indexes, so many investors already own a small slice through funds. In Walnut you can add HSIC to a basket alongside other health care distribution or dental names and give the group a stated thesis and target weights.
Is HSIC a dental stock or a medical stock?
+
Predominantly dental. Dental is the larger and more profitable side of the business and drives most of the sentiment on the stock, while medical distribution is a sizeable but low-margin second leg that activist investor Ananym has argued should be reviewed for divestiture.
Why does KKR own a stake in Henry Schein?
+
KKR built a position of roughly 12% in January 2025 and negotiated two board seats (Max Lin and William Daniel joined as directors), with a standstill limit later raised from 14.9% to 19.9%. The stated aim is value creation through margin improvement and portfolio focus rather than an outright acquisition.
Does Henry Schein pay a dividend?
+
No. Henry Schein has historically returned capital through share repurchases rather than a dividend, which is worth knowing if the position is being considered for an income-oriented allocation.
Why are the reported operating margins so low?
+
Because most of the revenue is pass-through distribution. GAAP operating margin was under 5% in Q2 2026, but that blends a very thin distribution business with a technology segment earning roughly 27%. The consolidated number tells you more about revenue mix than about the quality of the underlying units.
What is the restructuring plan and when does it end?
+
It is a value-creation program launched in 2025 targeting more than $200 million of margin improvement, working through pricing, procurement, product mix and cost structure. Management expects related charges to continue through 2027, so GAAP earnings will trail the non-GAAP figures used in guidance for at least another year and a half.
What would break the thesis?
+
A stall in dental patient traffic that keeps consumables and equipment demand soft, tariffs or supplier terms that compress gross margin faster than the cost program can offset, integration problems or an impairment in the acquired specialty portfolio, or evidence that the Q2 2026 margin improvement was a one-off rather than a run rate.
How did Henry Schein do in its latest quarter?
+
Second-quarter 2026 sales were about $3.46 billion, up roughly 6.7% year over year, with internal local-currency growth of about 4.6%. Non-GAAP EPS of ~$1.27 beat the ~$1.24 consensus, the fourth straight quarterly beat, and full-year guidance was raised. GAAP net income was lower at ~$94 million because of restructuring charges. Q3 results are scheduled for November 3, 2026, with consensus at ~$1.36 of EPS on ~$3.48 billion of sales.
How has HSIC stock performed in 2026?
+
As of October 16, 2026 the stock closed at $86.84, up ~13% year to date and ~40% over the past year, within a 52-week range of ~$62.05 to ~$92.18. The average target among 15 analysts is ~$97, though Leerink and Baird both trimmed their targets in mid-October ahead of Q3 results.
Who is Henry Schein's new CFO?
+
Emmanuel Caprais, who was CFO of industrial manufacturer ITT from 2020 until May 2026 and earlier held finance roles at Magneti Marelli and Valeo. He joined as a senior financial advisor on October 12, 2026 and becomes CFO on November 4, 2026, reporting to CEO Fred Lowery. Ronald South, who spent 18 years at the company and four as CFO, moves into a senior advisory role.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Henry Schein, Inc.'s investor relations page or your broker before making investment decisions.